CMS (Centers for Medicare and Medicaid Services) makes Guidant, Medtronic wait on ICDs (implantable cardioverter defibrillators) coverage decision
This article was originally published in Clinica
Guidant and Medtronic will have to wait a few more weeks before the Centers for Medicare and Medicaid Services decides whether Medicare should cover the use of implanted cardioverter defibrillators (ICDs) to prevent sudden cardiac arrest in patients whose heart can no longer pump adequately as a result of a heart attack.
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.